Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Belinostat - Valerio Therapeutics

Next Previous
Drug Profile

Belinostat - Valerio Therapeutics

Alternative Names: Beleodaq; CLN-9; PDX 101; PX-105684; PXD 101

Latest Information Update: 05 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator TopoTarget
  • Developer Acrotech Biopharma; CIMA- Universidad de Navarra; Emory University; National Cancer Institute (USA); Servier; TopoTarget; Valerio Therapeutics
  • Class Acrylamides; Antineoplastics; Hydroxamic acids; Small molecules; Sulfonamides
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Peripheral T-cell lymphoma; Malignant thymoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Peripheral T-cell lymphoma
  • Phase II B-cell lymphoma; Glioblastoma
  • Phase I/II Non-small cell lung cancer
  • Phase I Breast cancer; Ovarian cancer; Prostate cancer
  • Suspended Chondrosarcoma
  • No development reported Acute myeloid leukaemia; Bladder cancer; Carcinoma; Colorectal cancer; Cutaneous T-cell lymphoma; Fallopian tube cancer; Liver cancer; Lymphoma; Malignant thymoma; Malignant-mesothelioma; Myelodysplastic syndromes; Peritoneal cancer; Small cell lung cancer; Soft tissue sarcoma; Solid tumours
  • Discontinued Multiple myeloma

Most Recent Events

  • 05 Feb 2025 Belinostat is still in phase I trials for Ovarian cancer, Prostate cancer and Breast cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT04703920)
  • 02 Jan 2025 Valerio Therapeutics completes phase I trials in Ovarian cancer, Prostate cancer and Breast cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT04703920)
  • 28 Apr 2024 No recent reports of development identified for phase-I development in Breast-cancer(Combination therapy, Metastatic disease, Second-line therapy or greater) in USA (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top